Cargando…

Effect of Comorbidities on Inflammatory Bowel Disease-Related Colorectal Cancer: A Nationwide Inpatient Review

Introduction  The risk of inflammatory bowel disease-associated colorectal cancer (IBD-CRC) is known to increase with primary sclerosing cholangitis (PSC) and a family history of CRC. However, the impact of comorbidities such as liver disease, obesity, diabetes, chronic lung, heart, and renal diseas...

Descripción completa

Detalles Bibliográficos
Autores principales: Forlemu, Arnold N, Nana Sede Mbakop, Raissa, Aslam, Shehroz, Ansari, Zaid, Srinivasan, Indu, Chuang, Keng-Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9433811/
https://www.ncbi.nlm.nih.gov/pubmed/36059351
http://dx.doi.org/10.7759/cureus.27599
_version_ 1784780709872795648
author Forlemu, Arnold N
Nana Sede Mbakop, Raissa
Aslam, Shehroz
Ansari, Zaid
Srinivasan, Indu
Chuang, Keng-Yu
author_facet Forlemu, Arnold N
Nana Sede Mbakop, Raissa
Aslam, Shehroz
Ansari, Zaid
Srinivasan, Indu
Chuang, Keng-Yu
author_sort Forlemu, Arnold N
collection PubMed
description Introduction  The risk of inflammatory bowel disease-associated colorectal cancer (IBD-CRC) is known to increase with primary sclerosing cholangitis (PSC) and a family history of CRC. However, the impact of comorbidities such as liver disease, obesity, diabetes, chronic lung, heart, and renal disease, and psychiatric illness on the risk of IBD-CRC remains unclear. We evaluated the effect of these comorbidities on the risk of IBD-CRC. Methods A retrospective review from 2009 to 2014 was conducted using the National Inpatient Sample data for adults 18 years and older. Patients with IBD (360,892), of whom 2,831 had CRC were identified using the International Classification of Diseases, Ninth Revision codes (ICD-9). Data on comorbidities were also obtained. Adjusted odds ratios (aOR) and confidence intervals (CI) were computed via logistic regression to evaluate the effect of comorbidities on the risk of IBD-CRC; the p-value was set at <0.05. Results The mean age of IBD patients in this study was 52.36±0.03. A majority of the patients with IBD-CRC were white and were significantly older compared to those without cancer (60 vs 52 years, p<0.05). The risk of colon cancer in IBD was increased by having a non-cholestatic liver disease (aOR 1.51, CI 1.23-1.86, p<0.01). Also, patients younger than 50 years with liver disease were at an increased risk of IBD-associated colon cancer in comparison to older patients (aOR 1.83 vs 1.34, p<0.05). Notably, diabetes, chronic pulmonary disease, renal failure, psychiatric illnesses, and rheumatoid diseases, were inversely associated with the risk of IBD-CRC (p<0.05). After stratifying by IBD subtypes, non-cholestatic liver disease was still independently associated with a higher risk for colon cancer in patients with ulcerative colitis or Crohn's disease (ulcerative colitis: aOR 1.43, CI 1.08-1.89; Crohn's disease: aOR 1.46, CI 1.10-2.00). Conclusions Patients with IBD who have non-cholestatic liver disease might have a higher risk for colon cancer, even at a younger age. These patients may require close colon cancer surveillance.
format Online
Article
Text
id pubmed-9433811
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-94338112022-09-03 Effect of Comorbidities on Inflammatory Bowel Disease-Related Colorectal Cancer: A Nationwide Inpatient Review Forlemu, Arnold N Nana Sede Mbakop, Raissa Aslam, Shehroz Ansari, Zaid Srinivasan, Indu Chuang, Keng-Yu Cureus Internal Medicine Introduction  The risk of inflammatory bowel disease-associated colorectal cancer (IBD-CRC) is known to increase with primary sclerosing cholangitis (PSC) and a family history of CRC. However, the impact of comorbidities such as liver disease, obesity, diabetes, chronic lung, heart, and renal disease, and psychiatric illness on the risk of IBD-CRC remains unclear. We evaluated the effect of these comorbidities on the risk of IBD-CRC. Methods A retrospective review from 2009 to 2014 was conducted using the National Inpatient Sample data for adults 18 years and older. Patients with IBD (360,892), of whom 2,831 had CRC were identified using the International Classification of Diseases, Ninth Revision codes (ICD-9). Data on comorbidities were also obtained. Adjusted odds ratios (aOR) and confidence intervals (CI) were computed via logistic regression to evaluate the effect of comorbidities on the risk of IBD-CRC; the p-value was set at <0.05. Results The mean age of IBD patients in this study was 52.36±0.03. A majority of the patients with IBD-CRC were white and were significantly older compared to those without cancer (60 vs 52 years, p<0.05). The risk of colon cancer in IBD was increased by having a non-cholestatic liver disease (aOR 1.51, CI 1.23-1.86, p<0.01). Also, patients younger than 50 years with liver disease were at an increased risk of IBD-associated colon cancer in comparison to older patients (aOR 1.83 vs 1.34, p<0.05). Notably, diabetes, chronic pulmonary disease, renal failure, psychiatric illnesses, and rheumatoid diseases, were inversely associated with the risk of IBD-CRC (p<0.05). After stratifying by IBD subtypes, non-cholestatic liver disease was still independently associated with a higher risk for colon cancer in patients with ulcerative colitis or Crohn's disease (ulcerative colitis: aOR 1.43, CI 1.08-1.89; Crohn's disease: aOR 1.46, CI 1.10-2.00). Conclusions Patients with IBD who have non-cholestatic liver disease might have a higher risk for colon cancer, even at a younger age. These patients may require close colon cancer surveillance. Cureus 2022-08-02 /pmc/articles/PMC9433811/ /pubmed/36059351 http://dx.doi.org/10.7759/cureus.27599 Text en Copyright © 2022, Forlemu et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Internal Medicine
Forlemu, Arnold N
Nana Sede Mbakop, Raissa
Aslam, Shehroz
Ansari, Zaid
Srinivasan, Indu
Chuang, Keng-Yu
Effect of Comorbidities on Inflammatory Bowel Disease-Related Colorectal Cancer: A Nationwide Inpatient Review
title Effect of Comorbidities on Inflammatory Bowel Disease-Related Colorectal Cancer: A Nationwide Inpatient Review
title_full Effect of Comorbidities on Inflammatory Bowel Disease-Related Colorectal Cancer: A Nationwide Inpatient Review
title_fullStr Effect of Comorbidities on Inflammatory Bowel Disease-Related Colorectal Cancer: A Nationwide Inpatient Review
title_full_unstemmed Effect of Comorbidities on Inflammatory Bowel Disease-Related Colorectal Cancer: A Nationwide Inpatient Review
title_short Effect of Comorbidities on Inflammatory Bowel Disease-Related Colorectal Cancer: A Nationwide Inpatient Review
title_sort effect of comorbidities on inflammatory bowel disease-related colorectal cancer: a nationwide inpatient review
topic Internal Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9433811/
https://www.ncbi.nlm.nih.gov/pubmed/36059351
http://dx.doi.org/10.7759/cureus.27599
work_keys_str_mv AT forlemuarnoldn effectofcomorbiditiesoninflammatoryboweldiseaserelatedcolorectalcanceranationwideinpatientreview
AT nanasedembakopraissa effectofcomorbiditiesoninflammatoryboweldiseaserelatedcolorectalcanceranationwideinpatientreview
AT aslamshehroz effectofcomorbiditiesoninflammatoryboweldiseaserelatedcolorectalcanceranationwideinpatientreview
AT ansarizaid effectofcomorbiditiesoninflammatoryboweldiseaserelatedcolorectalcanceranationwideinpatientreview
AT srinivasanindu effectofcomorbiditiesoninflammatoryboweldiseaserelatedcolorectalcanceranationwideinpatientreview
AT chuangkengyu effectofcomorbiditiesoninflammatoryboweldiseaserelatedcolorectalcanceranationwideinpatientreview